What is the recommended treatment for mandibular osteosarcoma?

Treatment of Mandibular Osteosarcoma

Mandibular osteosarcoma requires multimodal treatment with neoadjuvant chemotherapy followed by wide surgical resection with negative margins, treating it identically to high-grade osteosarcoma at other sites 1.

Treatment Algorithm by Grade

High-Grade Mandibular Osteosarcoma (Most Common)

Primary treatment consists of:

1. Neoadjuvant chemotherapy using doxorubicin, cisplatin, high-dose methotrexate (HD-MTX), and ifosfamide 1

   • For patients >40 years: preferred regimen combines doxorubicin, cisplatin, and ifosfamide 1
   • For patients <40 years: MAP protocol (methotrexate, doxorubicin, cisplatin) 2
   • Neoadjuvant chemotherapy improves disease-free survival and increases clear margin rates from 50% to 68% 3

2. Wide surgical resection with negative margins

   • This is the strongest prognostic factor for survival 3, 4
   • Free flap reconstruction should be planned 3
   • Soft tissue margin involvement is strongly associated with recurrence (p=0.0024) 4
   • Total mandibulectomy is NOT necessary; resection should be tailored to tumor size with adequate margins 4

3. Adjuvant therapy based on surgical margins:

   • Radiation therapy when complete surgery is not feasible or with positive margins 1
   • Heavy particle RT (proton beam therapy or carbon ion) and IMRT can be considered for unresectable tumors 1
   • Continue adjuvant chemotherapy per protocol 1

Low-Grade Mandibular Osteosarcoma (Rare)

• Surgery alone with wide margins 1
• No chemotherapy indicated 1

Critical Guideline Principles

The 2021 ESMO-EURACAN-GENTURIS-ERN PaedCan guidelines explicitly state that high-grade craniofacial osteosarcoma should be treated the same way as high-grade osteosarcoma of other sites 1. This is a Level IV, Grade B recommendation that directly addresses mandibular location.

Important Caveats

Intermediate-grade tumors behave like high-grade tumors in terms of metastatic-free and disease-free survival, so they should receive the same aggressive multimodal treatment 3.

Age considerations matter: The chemotherapy regimen differs based on age, with patients >40 years receiving doxorubicin, cisplatin, and ifosfamide (without HD-MTX due to tolerability) 1, 2.

Margin status is paramount: Soft tissue involvement and positive margins are the limiting factors for local control 4. The relationship between resection size and tumor size should be approximately 1.5:1, not requiring total mandibulectomy 4.

Recurrent Disease

• Primarily surgical for isolated recurrences 1
• Second-line chemotherapy options include ifosfamide or cyclophosphamide with etoposide and/or carboplatin 1
• Alternative agents: gemcitabine and docetaxel 1, 2

Common Pitfalls to Avoid

Do not skip chemotherapy for high-grade mandibular osteosarcoma. Despite historical controversy about chemotherapy effectiveness in jaw osteosarcomas 5, 6, 7, current guidelines are clear that craniofacial high-grade osteosarcomas receive the same treatment as appendicular osteosarcomas 1. The largest retrospective series (111 patients) demonstrated that neoadjuvant chemotherapy improves disease-free and metastasis-free survival 3.

Do not perform unnecessarily extensive resections. Total mandibulectomy does not improve local control or survival compared to appropriately sized resections with clear margins 4.

Do not underestimate intermediate-grade tumors. These require the same aggressive treatment as high-grade tumors 3.